Article Versions Notes

Kaji K, Takeda S, Iwai S, Nishimura N, Sato S, Namisaki T, Akahane T, Yoshiji H. Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. Antioxidants. 2024; 13(11):1415. https://doi.org/10.3390/antiox13111415

Kaji, Kosuke, Soichi Takeda, Satoshi Iwai, Norihisa Nishimura, Shinya Sato, Tadashi Namisaki, Takemi Akahane, and Hitoshi Yoshiji. 2024. "Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis" Antioxidants 13, no. 11: 1415. https://doi.org/10.3390/antiox13111415

Kaji, K., Takeda, S., Iwai, S., Nishimura, N., Sato, S., Namisaki, T., Akahane, T., & Yoshiji, H. (2024). Imeglimin Halts Liver Damage by Improving Mitochondrial Dysfunction in a Nondiabetic Male Mouse Model of Metabolic Dysfunction-Associated Steatohepatitis. Antioxidants, 13(11), 1415. https://doi.org/10.3390/antiox13111415